pembrolizumab,lenvatinib
merck,eisai
['leap-002']
#esmo22 day 2 highlights: improved clinical benefit in desmoid tumors, unexpected results from leap-002, and impressive immunotherapy regimen for cervical cancer. 
Plan, consolidate data, and synthesize insights from life science conferences and social media with https://t.co/Fhm0QpaU5o, a product of @ZoomRx.